Another Activist Investor Joins Calls For GSK Leadership Review

Bluebell Capital Has Already Ousted One CEO

 
• By Andrew McConaghie
GSK
The company's share price has underperformed in recent years, and its UK rival AstraZeneca now has a market cap nearly double GSK's £70bn.

More from Business

More from Scrip